SVB Leerink analyst Andrew Berens maintains Arvinas (NASDAQ:ARVN) with a Outperform and lowers the price target from $89 to $74.
Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote In Favor Of NARCAN Nasal Spray, A Nonprescription Opioid Overdose Reversal Agent For Over-The-Counter Use
If approved by the FDA, NARCAN Nasal Spray will be the first 4 mg naloxone nasal spray switched from prescription status to over-the-counter use
GAITHERSBURG, Md., Feb. 15, 2023 (GLOBE NEWSWIRE) --
